<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2022</volume><submitter>Zuin M</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>To review and compare the PON-1 arylesterase activity between coronary artery disease (CAD) and non-CAD patients.&lt;h4>Methods&lt;/h4>Data were obtained by searching MEDLINE and Scopus for all investigations published between January 1, 2000 and March 1, 2021 comparing PON-1 arylesterase activity between CAD and controls.&lt;h4>Results&lt;/h4>Twenty studies, based on 5417 patients, met the inclusion criteria and were included in the analysis. A random effect model revealed that PON-1 arylesterase activity was significantly lower in the CAD group compared to controls (SMD = -0.587, 95%CI = -0.776 to -0.339, &lt;i>p&lt;/i> &lt; 0.0001, &lt;i>I&lt;/i> &lt;sup>2&lt;/sup> = 92.3%). In CAD patients, the PON-1 arylesterase activity was significantly higher among CAD patients without diabetes mellitus (DM) compared t</pubmed_abstract><journal>Disease markers</journal><pagination>4264314</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8930235</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis.</pubmed_title><pmcid>PMC8930235</pmcid><pubmed_authors>Cervellati C</pubmed_authors><pubmed_authors>Passaro A</pubmed_authors><pubmed_authors>Bosi C</pubmed_authors><pubmed_authors>D'Amuri A</pubmed_authors><pubmed_authors>Marsillach J</pubmed_authors><pubmed_authors>Zuin M</pubmed_authors><pubmed_authors>Zuliani G</pubmed_authors><pubmed_authors>Trentini A</pubmed_authors><pubmed_authors>Roncon L</pubmed_authors><pubmed_authors>Mackness M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis.</name><description>&lt;h4>Aim&lt;/h4>To review and compare the PON-1 arylesterase activity between coronary artery disease (CAD) and non-CAD patients.&lt;h4>Methods&lt;/h4>Data were obtained by searching MEDLINE and Scopus for all investigations published between January 1, 2000 and March 1, 2021 comparing PON-1 arylesterase activity between CAD and controls.&lt;h4>Results&lt;/h4>Twenty studies, based on 5417 patients, met the inclusion criteria and were included in the analysis. A random effect model revealed that PON-1 arylesterase activity was significantly lower in the CAD group compared to controls (SMD = -0.587, 95%CI = -0.776 to -0.339, &lt;i>p&lt;/i> &lt; 0.0001, &lt;i>I&lt;/i> &lt;sup>2&lt;/sup> = 92.3%). In CAD patients, the PON-1 arylesterase activity was significantly higher among CAD patients without diabetes mellitus (DM) compared t</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T20:23:35.523Z</modification><creation>2025-04-04T20:23:35.523Z</creation></dates><accession>S-EPMC8930235</accession><cross_references><pubmed>35308142</pubmed><doi>10.1155/2022/4264314</doi></cross_references></HashMap>